ClearPoint Neuro (CLPT) Earnings Dates, Call Summary & Reports

Compare

431 Followers

Earnings Data

Report Date

May 12, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.26

Last Year’s EPS

-0.22

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 2 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Mar 17, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call conveyed strong commercial and clinical momentum — year-over-year revenue growth, a significantly larger cash balance from recent financing, important regulatory clearances (PRISM 1.5T, CE for 3.X), an expanding partner and clinical footprint (>60 partners, 25+ trials), and an operational roadmap (CAL facility, robotics). At the same time, the business is managing notable near-term headwinds from increased operating expenses (notably G&A +38%), elevated cash burn from operations ($23.9M), higher interest expense following financing, acquisition-related one-time costs and assumed liabilities, and some removed upside due to stricter FDA positioning on rare-disease approval pathways. Management provided a constructive 2026 revenue guide ($52M–$56M) but acknowledged regulatory and integration risks that could affect timing of upside.

Company Guidance

On the call management set 2026 revenue guidance at $52.0–$56.0 million — a range tightened to reflect recent FDA communications around rare-disease approvals and integration priorities from the November 20, 2025 Eris acquisition (Eris contributed $1.2M of 2025 revenue and historically ran roughly $8–9M a year) — while noting FY2025 revenue was $37.0M (up from $31.4M in 2024) and Q4/2025 revenue was $10.4M (vs. $7.8M a year earlier). They reiterated expectations that all four core product segments (pre‑commercial biologics & drug delivery, neurosurgery navigation & robotics, laser therapy & access, and neurocritical management/EarFlo) will each grow in the double digits in 2026, highlighted a FY2025 gross margin of ~61% (Q4 62%), and summarized FY2025 expenses of R&D $13.9M, sales & marketing $16.5M, and G&A $16.5M. Key operational metrics supporting the outlook include cash & equivalents of $45.9M at 12/31/2025, net cash used in operations of $23.9M in 2025, an installed base of >150 global centers, >60 active biopharma partners, >25 active clinical trials across >15 indications, and >10 partner programs in some form of FDA expedited review; management said the guidance excludes meaningful commercial drug‑delivery revenue (so regulatory upside would be incremental) and reiterated a longer‑term aim to capture ~20% of a combined $1.0B market (~$200M revenue) on the path toward a potential $500M business, with sustainable organic growth expectations in the mid‑teens to ~20% range.

Full-Year and Q4 Revenue Growth

Total revenue for FY2025 was $37.0M, up from $31.4M in 2024 (+17.8%). Fourth quarter revenue was $10.4M versus $7.8M a year earlier (+33.3%), representing the strongest financial quarter of 2025.

Biologics & Drug Delivery Momentum

Biologics and drug delivery revenue increased to $19.0M in 2025 from $17.3M in 2024 (+10%). Q4 biologics & drug delivery revenue rose 23% year-over-year to $5.2M driven by higher disposable product demand as partner trials progressed.

Strengthened Balance Sheet

Cash and cash equivalents at 12/31/2025 were $45.9M versus $20.1M at 12/31/2024 (increase of $25.8M). The increase largely resulted from net proceeds of notes payable and a stock offering (~$51.4M) plus cash acquired from the Eris acquisition ($1.1M).

Broad Partner Ecosystem and Clinical Footprint

More than 60 active biopharma partners, participation in 25+ active clinical trials, exploration across 15+ indications, and 10+ partner programs accepted to some form of FDA expedited review — establishing diversified clinical engagement and future commercial opportunity.

Regulatory and Product Milestones

Key regulatory/product achievements in 2025: PRISM system received FDA clearance for 1.5T MRI compatibility; 3.X software obtained CE marking under a new European Notified Body; EarFlo product line commercialized through the Eris acquisition; PMDA process initiated in Japan.

Installed Base, New Offerings and Commercial Progress

Installed base of more than 150 global centers, full market release of PRISM Laser System and iCT solution, successful limited market release of 3.X software with performance benefits (accuracy, procedure time, radiation dose), and early robotic platform development with planned preclinical studies at the CAL facility in 2026.

2026 Revenue Guidance and Growth Targets

Management guided 2026 revenue of $52.0M–$56.0M (implying ~+40–+51% vs. FY2025) and expects all four core product segments to grow in the double digits in 2026; longer-term target to capture 20% of a combined $1.0B market (phase one target of $200M ARR) and to build toward a larger commercial opportunity thereafter.

CAL Facility and High-Value Preclinical Opportunity

Advanced Laboratories (CAL) in Torrey Pines is operational for smaller preclinical studies now with full construction targeted to complete H2 2026; management noted a single GLP study could represent $15M–$20M of revenue, representing material upside when capabilities are fully online.

ClearPoint Neuro (CLPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CLPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 12, 2026	2026 (Q1)	-0.26 / -	-0.22	―	―	―
Mar 17, 2026	2025 (Q4)	-0.20 / -0.26	-0.2	-30.00% (-0.06)	―
Nov 06, 2025	2025 (Q3)	-0.20 / -0.21	-0.18	-16.67% (-0.03)	―
Aug 12, 2025	2025 (Q2)	-0.20 / -0.21	-0.16	-31.25% (-0.05)	―
May 13, 2025	2025 (Q1)	-0.16 / -0.22	-0.16	-37.50% (-0.06)	―
Feb 26, 2025	2024 (Q4)	-0.16 / -0.20	-0.18	-11.11% (-0.02)
Nov 07, 2024	2024 (Q3)	-0.17 / -0.18	-0.2	10.00% (+0.02)
Aug 07, 2024	2024 (Q2)	-0.20 / -0.16	-0.29	44.83% (+0.13)
May 07, 2024	2024 (Q1)	-0.19 / -0.16	-0.23	30.43% (+0.07)	―
Mar 12, 2024	2023 (Q4)	-0.20 / -0.18	-0.18	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CLPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 17, 2026	$11.16	$9.61	-13.93%
Nov 06, 2025	$18.23	$15.81	-13.27%
Aug 12, 2025	$10.54	$11.92	+13.09%
May 13, 2025	$14.20	$12.43	-12.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Clearpoint Neuro, Inc. (CLPT) report earnings?

Clearpoint Neuro, Inc. (CLPT) is schdueled to report earning on May 12, 2026, After Close (Confirmed).

What is Clearpoint Neuro, Inc. (CLPT) earnings time?

Clearpoint Neuro, Inc. (CLPT) earnings time is at May 12, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CLPT EPS forecast?

CLPT EPS forecast for the fiscal quarter 2026 (Q1) is -0.26.